scholarly journals Citrate-Coated Magnetic Polyethyleneimine Composites for Plasmid DNA Delivery into Glioblastoma

Polymers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 2228
Author(s):  
Ken Cham-Fai Leung ◽  
Kathy W. Y. Sham ◽  
Josie M. Y. Lai ◽  
Yi-Xiang J. Wang ◽  
Chi-Hin Wong ◽  
...  
Keyword(s):  
Cellular Uptake ◽  
Plasmid Dna ◽  
Green Fluorescence Protein ◽  
Superparamagnetic Iron Oxide ◽  
Blue Staining ◽  
Luciferase Expression ◽  
Ultrasmall Superparamagnetic Iron Oxide ◽  
Low Cytotoxicity ◽  
Optimal Efficiency

Several ternary composites that are based on branched polyethyleneimine (bPEI 25 kDa, polydispersity 2.5, 0.1 or 0.2 ng), citrate-coated ultrasmall superparamagnetic iron oxide nanoparticles (citrate-NPs, 8–10 nm, 0.1, 1.0, or 2.5 µg), and reporter circular plasmid DNA pEGFP-C1 or pRL-CMV (pDNA 0.5 µg) were studied for optimization of the best composite for transfection into glioblastoma U87MG or U138MG cells. The efficiency in terms of citrate-NP and plasmid DNA gene delivery with the ternary composites could be altered by tuning the bPEI/citrate-NP ratios in the polymer composites, which were characterized by Prussian blue staining, in vitro magnetic resonance imaging as well as green fluorescence protein and luciferase expression. Among the composites prepared, 0.2 ng bPEI/0.5 μg pDNA/1.0 µg citrate-NP ternary composite possessed the best cellular uptake efficiency. Composite comprising 0.1 ng bPEI/0.5 μg pDNA/0.1 μg citrate-NP gave the optimal efficiency for the cellular uptake of the two plasmid DNAs to the nucleus. The best working bPEI concentration range should not exceed 0.2 ng/well to achieve a relatively low cytotoxicity.

scholarly journals In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 394 ◽  
Author(s):  
Viktor Maurer ◽  
Selin Altin ◽  
Didem Ag Seleci ◽  
Ajmal Zarinwall ◽  
Bilal Temel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cellular Uptake ◽  
Sirna Delivery ◽  
Superparamagnetic Iron Oxide ◽  
Cost Effective ◽  
Chemotherapeutic Agents ◽  
Therapy Outcome ◽  
Ionic Surfactant ◽  
Combinational Therapy

Even though the administration of chemotherapeutic agents such as erlotinib is clinically established for the treatment of breast cancer, its efficiency and the therapy outcome can be greatly improved using RNA interference (RNAi) mechanisms for a combinational therapy. However, the cellular uptake of bare small interfering RNA (siRNA) is insufficient and its fast degradation in the bloodstream leads to a lacking delivery and no suitable accumulation of siRNA inside the target tissues. To address these problems, non-ionic surfactant vesicles (niosomes) were used as a nanocarrier platform to encapsulate Lifeguard (LFG)-specific siRNA inside the hydrophilic core. A preceding entrapment of superparamagnetic iron-oxide nanoparticles (FexOy-NPs) inside the niosomal bilayer structure was achieved in order to enhance the cellular uptake via an external magnetic manipulation. After verifying a highly effective entrapment of the siRNA, the resulting hybrid niosomes were administered to BT-474 cells in a combinational therapy with either erlotinib or trastuzumab and monitored regarding the induced apoptosis. The obtained results demonstrated that the nanocarrier successfully caused a downregulation of the LFG gene in BT-474 cells, which led to an increased efficacy of the chemotherapeutics compared to plainly added siRNA. Especially the application of an external magnetic field enhanced the internalization of siRNA, therefore increasing the activation of apoptotic signaling pathways. Considering the improved therapy outcome as well as the high encapsulation efficiency, the formulated hybrid niosomes meet the requirements for a cost-effective commercialization and can be considered as a promising candidate for future siRNA delivery agents.

scholarly journals Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids

2021 ◽  
Vol 14 (9) ◽  
pp. 841
Author(s):  
Jian-Ming Lü ◽  
Zhengdong Liang ◽  
Dongliang Liu ◽  
Bin Zhan ◽  
Qizhi Yao ◽  
...  
Keyword(s):  
Nucleic Acids ◽  
Plasmid Dna ◽  
Glycolic Acid ◽  
Growth Factor Receptor ◽  
Green Fluorescence Protein ◽  
Active Targeting ◽  
Single Chain ◽  
Targeting Delivery

We previously reported a new polymer, lactic-co-glycolic acid-polyethylenimine (LGA-PEI), as an improved nanoparticle (NP) delivery for therapeutic nucleic acids (TNAs). Here, we further developed two antibody (Ab)-conjugated LGA-PEI NP technologies for active-targeting delivery of TNAs. LGA-PEI was covalently conjugated with a single-chain variable fragment antibody (scFv) against mesothelin (MSLN), a biomarker for pancreatic cancer (PC), or a special Ab fragment crystallizable region-binding peptide (FcBP), which binds to any full Ab (IgG). TNAs used in the current study included tumor suppressor microRNA mimics (miR-198 and miR-520h) and non-coding RNA X-inactive specific transcript (XIST) fragments; green fluorescence protein gene (GFP plasmid DNA) was also used as an example of plasmid DNA. MSLN scFv-LGA-PEI NPs with TNAs significantly improved their binding and internalization in PC cells with high expression of MSLN in vitro and in vivo. Anti-epidermal growth factor receptor (EGFR) monoclonal Ab (Cetuximab) binding to FcBP-LGA-PEI showed active-targeting delivery of TNAs to EGFR-expressing PC cells.

scholarly journals In Vitro Characterization of Magnetic Resonance Imaging Contrast Agents for Molecular Imaging.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3944-3944
Author(s):  
Zhi Yu ◽  
Michael Grafe ◽  
Heike Meyborg ◽  
Eckart Fleck ◽  
Yangqiu Li
Keyword(s):  
Endothelial Cells ◽  
Molecular Imaging ◽  
Cellular Uptake ◽  
Umbilical Vein ◽  
Biological Properties ◽  
Blue Staining ◽  
Iron Core ◽  
Coated Particles ◽  
Coated Particle

Abstract The aim of this work was to evaluate the biological properties of one citrate-coated and two different dextran-coated paramagnetic particles with comparable size (iron core 4–10 nm). Endothelial cells from humans and mice as well as human macrophages were incubated for different time intervals with different particle suspensions. The cellular uptake was semi-quantitatively measured using the Prussian blue staining and, in addition, by cellular iron content. Furthermore the effect of known inhibitors of endocytosis was evaluated. In addition, it was evaluated whether linking of monoclonal antibodies to dextran-coated particles can make them bind specifically to certain cell surface structures. The results showed that the bEnd.3 cell line, human umbilical vein endothelial cells (HUVECs) and THP-1/macrophage cell lines internalize paramagnetic particles. The ranking of cellular uptake was: VSOP > CMD-coated particles >> CLIO. The carboxydextran-coated SPIO uptake by endothelial cells is reduced by colchicine (50%). Conversely, cytochalasin B down-regulates the endocytosis of citrate-coated particle. Our data imply that the major mechanism of uptake would be pinocytosis for the VSOP and phagocytosis for the carboxydextran-coated particle CMD. The different surface coating can influence not only the quantity of the internalization, but also the pathway of internalization. CLIO linked to CD40 antibodies or to CD62E antibodies bound significantly better than IgG-linked CLIO. This was true especially for the anti-CD40-CLIO constructs where fluorescence increased two fold. Comparable results were observed with anti-CD62E-CLIO constructs; however, increase in fluorescence was higher than with CD40 binding; it increased on 3.9-fold (median) and 4.5-fold (mean). In conclusions, the binding of antibody-conjugated CLIO to the antigen-expressing cells was specific, with an affinity similar to that of the free antibody. Thus, it seems feasible to use antibody linked SPIOs for molecular imaging.

Preparation and In Vitro Cellular Uptake Assessment of Multifunctional Rubik-Like Magnetic Nano-Assemblies

2019 ◽  
Vol 19 (6) ◽  
pp. 3301-3309
Author(s):  
Xiawen Zheng ◽  
Yuejian Chen ◽  
Zhiming Wang ◽  
Lina Song ◽  
Yu Zhang ◽  
...  
Keyword(s):  
Oleic Acid ◽  
Folic Acid ◽  
Cellular Uptake ◽  
Hela Cells ◽  
Drug Loading ◽  
Superparamagnetic Iron Oxide ◽  
Drug Carriers ◽  
High Drug ◽  
High Drug Loading

Through self-assembly of nanoparticles into high-order and stable structures of cubic clusters, high drug-loading rubik-like magnetic nano-assemblies (MNAs), possessing folic acid targeting and strong magnetism-enhanced cellular uptake capabilities, were built. In this study, the core of the cubic drug assemblies consisted of four monodisperse superparamagnetic iron oxide nanoparticles coated with layers of oleic acid (Fe3O4@OA), simultaneously encapsulating fluorescein, and Paclitaxol (Flu-MNAs and PTX-MNAs) for imaging and therapeutic applications. To enable preferential tumor cellular uptake by the nanocarriers, the outermost layer of Fe3O4 was functionalized with the new dual-oleic acid-polyethylene glycol-folic acid polymer (FA-PEG-Lys-OA2) as a “shell.” The drug carriers exhibited excellent stability and biocompatibility, and showed high drug loading and excellent magnetic response In Vitro. Furthermore, preliminary evaluations of the drug carriers with Hela cells showed effective cellular targeting capability. In addition, the cubic assemblies enhanced anticancer efficiency for Hela cells compared to bare drugs. Especially, the applied external magnetic field further improved the uptake of the vectors, and thereby enhanced the inhibitory effect. In brief, all these results suggested that cubic assemblies could serve as potential strategies for targeted anticancer therapies.

scholarly journals Arginine-based cationic liposomes for efficient in vitro plasmid DNA delivery with low cytotoxicity

2013 ◽  
pp. 1361 ◽  
Author(s):  
Shinji Takeoka ◽  
Sarker ◽  
Aoshima ◽  
Hokama ◽  
Inoue ◽  
...  
Keyword(s):  
Plasmid Dna ◽  
Dna Delivery ◽  
Cationic Liposomes ◽  
Low Cytotoxicity

scholarly journals TAMI-14. NANOPARTICLE DELIVERY OF PD-L1 CRISPR/CAS9 PLASMID DNA FOR ANTI-GLIOBLASTOMA IMMUNOTHERAPY

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii216-ii216
Author(s):  
Javier Fierro ◽  
An Tran ◽  
Chris Factoriza ◽  
Brandon Chin ◽  
Huanyu Dou
Keyword(s):  
Plasmid Dna ◽  
Viral Vectors ◽  
New Technologies ◽  
Transfection Efficiency ◽  
Guide Rna ◽  
Immune Balance ◽  
Main Challenge ◽  
Low Cytotoxicity

Abstract Glioblastoma multiforme (GBM) is a devastating cancer that develops from astrocytes in the brain. GBM is fast acting and kills 90% of patients within 5 years. Several immunotherapies have been developed to treat GBM, however, major challenges still persist. For example, checkpoint proteins such as programmed cell death protein 1 (PD-1) and its ligand, programmed death ligand 1 (PD-L1), are upregulated in GBM cells to evade the immune system. Targeting PD-L1 for genetic knockdown is thus a promising avenue for the treatment of GBM. However, PD-L1 protein inhibitors have been shown to cause immune overreaction and toxicity, therefore requiring new technologies. CRISPR/Cas9 gene editing has been widely used for the study and treatment of many diseases, but has not been extensively studied for the treatment of GBM. The main challenge is developing a gene delivery platform for the delivery of CRISPR/Cas9 plasmid DNA (pDNA). Many viral vectors have been used for the delivery of pDNA, but unfortunately are associated with high toxicity. Nanotechnology is emerging as a new platform for the delivery of pDNA as it shows high transfection efficiency with low cytotoxicity. We developed a cationic core-shell nanoparticle (NP) capable of carrying CRISPR/Cas9 pDNA. This plasmid contains multiple guide RNA (gRNA) expression cassettes for the knockdown of PD-L1. PDL1gRNA-CRISPR/Cas9pDNA-NPs were taken up by U87 cells within 30 minutes, and entered into the nucleus at 2 hours. The effective delivery of PDL1gRNA-CRISPR/Cas9pDNA-NPs led to the expression of PD-L1 gRNA and Cas9 enzyme, and the knockdown of PD-L1. Regulation of immune balance was determined after PD-L1 knockdown in vitro and in vivo. Our study shows the potential of NP-based PDL1gRNA-CRISPR/Cas9 delivery as an anti-GBM immunotherapy for clinical applications.

Sign in / Sign up

Export Citation Format

Share Document